Your browser doesn't support javascript.
loading
Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events.
Patel, Riyaz S; Schmidt, Amand F; Tragante, Vinicius; McCubrey, Raymond O; Holmes, Michael V; Howe, Laurence J; Direk, Kenan; Åkerblom, Axel; Leander, Karin; Virani, Salim S; Kaminski, Karol A; Muehlschlegel, Jochen D; Dubé, Marie-Pierre; Allayee, Hooman; Almgren, Peter; Alver, Maris; Baranova, Ekaterina V; Behlouli, Hassan; Boeckx, Bram; Braund, Peter S; Breitling, Lutz P; Delgado, Graciela; Duarte, Nubia E; Dufresne, Line; Eriksson, Niclas; Foco, Luisa; Gijsberts, Crystel M; Gong, Yan; Hartiala, Jaana; Heydarpour, Mahyar; Hubacek, Jaroslav A; Kleber, Marcus; Kofink, Daniel; Kuukasjärvi, Pekka; Lee, Vei-Vei; Leiherer, Andreas; Lenzini, Petra A; Levin, Daniel; Lyytikäinen, Leo-Pekka; Martinelli, Nicola; Mons, Ute; Nelson, Christopher P; Nikus, Kjell; Pilbrow, Anna P; Ploski, Rafal; Sun, Yan V; Tanck, Michael W T; Tang, W H Wilson; Trompet, Stella; van der Laan, Sander W.
Afiliação
  • Patel RS; Institute of Cardiovascular Science, Faculty of Population Health Science (R.S.P., A.F.S., L.J.H., K.D., J.D., A.D.H., F.W.A.).
  • Schmidt AF; Bart's Heart Centre, St Bartholomew's Hospital, London, United Kingdom (R.S.P., J.D., A. Timmis).
  • Tragante V; Institute of Cardiovascular Science, Faculty of Population Health Science (R.S.P., A.F.S., L.J.H., K.D., J.D., A.D.H., F.W.A.).
  • McCubrey RO; Division Heart and Lungs, Department of Cardiology (A.F.S., V.T. D.K., F.W.A.).
  • Holmes MV; Division Heart and Lungs, Department of Cardiology (A.F.S., V.T. D.K., F.W.A.).
  • Howe LJ; Intermountain Heart Institute, Intermountain Medical Center, Salt Lake City, UT (R.O.M., J.F.C., J.B.M., J.L.A.).
  • Direk K; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health (M.V.H.), University of Oxford, United Kingdom.
  • Åkerblom A; Medical Research Council Population Health Research Unit (M.V.H.), University of Oxford, United Kingdom.
  • Leander K; National Institute for Health Research Oxford Biomedical Research Centre (M.V.H.), University of Oxford, United Kingdom.
  • Virani SS; Institute of Cardiovascular Science, Faculty of Population Health Science (R.S.P., A.F.S., L.J.H., K.D., J.D., A.D.H., F.W.A.).
  • Kaminski KA; Institute of Cardiovascular Science, Faculty of Population Health Science (R.S.P., A.F.S., L.J.H., K.D., J.D., A.D.H., F.W.A.).
  • Muehlschlegel JD; Uppsala Clinical Research Center (A.A., N.E., S.J., E.H., C.H., B.L., D. Lindholm, A. Siegbahn, L.W.), Uppsala University, Sweden.
  • Dubé MP; Department of Medical Sciences, Cardiology (A.A., E.H., C.H., D. Lindholm), Uppsala University, Sweden.
  • Allayee H; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (K.L., U.d.F.).
  • Almgren P; Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Section of Cardiovascular Research, and Department of Medicine, Baylor College of Medicine, Houston, TX (S.S.V., C.M.B.).
  • Alver M; Department of Population Medicine and Civilization Disease Prevention (K.A.K.).
  • Baranova EV; Department of Cardiology (K.A.K., A. Szpakowicz).
  • Behlouli H; Harvard Medical School, Boston, MA (J.D.M., M.H. S.C.B.).
  • Boeckx B; Université de Montréal, QC, Canada (M.-P.D.).
  • Braund PS; Departments of Preventive Medicine and Biochemistry and Molecular Medicine (H.A., J.H.), Keck School of Medicine of USC, Los Angeles, CA.
  • Breitling LP; Department of Clinical Sciences, Lund University, Malmö, Sweden (P.A., O.M.).
  • Delgado G; Department of Biotechnology, Institute of Molecular and Cell Biology, University of Tartu, Estonia (M.A., A.M.).
  • Duarte NE; Division of Pharmacoepidemiology and Clinical Pharmacology (E.V.B., O.H.K., A.H.M.-v.d.Z.), University Medical Center Utrecht, the Netherlands.
  • Dufresne L; Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre (H.B., L.D., L.P., J.M.B.).
  • Eriksson N; Laboratory for Translational Genetics, Department of Human Genetics (B.B., D. Lambrechts).
  • Foco L; Laboratory for Translational Genetics, VIB Center for Cancer Biology, VIB, Belgium (B.B., D. Lambrechts).
  • Gijsberts CM; Department of Cardiovascular Sciences (P.S.B., C.P.N., N.J.S.) and Department of Health Sciences, University of Leicester, United Kingdom.
  • Gong Y; National Institute of Health Research (NIHR) Leicester Biomedical Research Centre (P.S.B., C.P.N.), Glenfield Hospital, Leicester, United Kingdom.
  • Hartiala J; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg (L.P.B., U.M., H.B.).
  • Heydarpour M; Vth Department of Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany (G.D., M. Kleber, W.M.).
  • Hubacek JA; Heart Institute, University of Sao Paulo, Brazil (N.E.D., A.C.P.).
  • Kleber M; Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre (H.B., L.D., L.P., J.M.B.).
  • Kofink D; Preventive and Genomic Cardiology, McGill University Health Centre, Montreal, QC, Canada (L.D., J.C.E., G.T.).
  • Kuukasjärvi P; Uppsala Clinical Research Center (A.A., N.E., S.J., E.H., C.H., B.L., D. Lindholm, A. Siegbahn, L.W.), Uppsala University, Sweden.
  • Lee VV; Institute for Biomedicine, Eurac Research, Affiliated Institute of the University of Lübeck, Bolzano, Italy (L.F.).
  • Leiherer A; Laboratory of Experimental Cardiology (C.M.G., B.D.H.).
  • Lenzini PA; Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics (Y.G., R.M.C.-D., J.A.J.).
  • Levin D; Departments of Preventive Medicine and Biochemistry and Molecular Medicine (H.A., J.H.), Keck School of Medicine of USC, Los Angeles, CA.
  • Lyytikäinen LP; Institute for Genetic Medicine (J.H.), Keck School of Medicine of USC, Los Angeles, CA.
  • Martinelli N; Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital (M.H.).
  • Mons U; Harvard Medical School, Boston, MA (J.D.M., M.H. S.C.B.).
  • Nelson CP; Centre for Experimental Medicine, Institut for Clinical and Experimental Medicine, Prague, Czech Republic (J.A.H., J.P.).
  • Nikus K; Vth Department of Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany (G.D., M. Kleber, W.M.).
  • Pilbrow AP; Division Heart and Lungs, Department of Cardiology (A.F.S., V.T. D.K., F.W.A.).
  • Ploski R; Department of Cardio-Thoracic Surgery (P.K.).
  • Sun YV; Department of Biostatistics and Epidemiology, Texas Heart Institute, Houston (V.-V.L.).
  • Tanck MWT; Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria (A.L., C.H.S., H.D.).
  • Tang WHW; Private University of the Principality of Liechtenstein, Triesen, Liechtenstein (A.L., C.H.S., H.D.).
  • Trompet S; Medical Central Laboratories, Feldkirch, Austria (A.L.).
  • van der Laan SW; Department of Genetics, Statistical Genomics Division (P.A.L., S.C.).
Circ Genom Precis Med ; 12(4): e002471, 2019 04.
Article em En | MEDLINE | ID: mdl-30897348
ABSTRACT

BACKGROUND:

Genetic variation at chromosome 9p21 is a recognized risk factor for coronary heart disease (CHD). However, its effect on disease progression and subsequent events is unclear, raising questions about its value for stratification of residual risk.

METHODS:

A variant at chromosome 9p21 (rs1333049) was tested for association with subsequent events during follow-up in 103 357 Europeans with established CHD at baseline from the GENIUS-CHD (Genetics of Subsequent Coronary Heart Disease) Consortium (73.1% male, mean age 62.9 years). The primary outcome, subsequent CHD death or myocardial infarction (CHD death/myocardial infarction), occurred in 13 040 of the 93 115 participants with available outcome data. Effect estimates were compared with case/control risk obtained from the CARDIoGRAMplusC4D consortium (Coronary Artery Disease Genome-wide Replication and Meta-analysis [CARDIoGRAM] plus The Coronary Artery Disease [C4D] Genetics) including 47 222 CHD cases and 122 264 controls free of CHD.

RESULTS:

Meta-analyses revealed no significant association between chromosome 9p21 and the primary outcome of CHD death/myocardial infarction among those with established CHD at baseline (GENIUS-CHD odds ratio, 1.02; 95% CI, 0.99-1.05). This contrasted with a strong association in CARDIoGRAMPlusC4D odds ratio 1.20; 95% CI, 1.18-1.22; P for interaction <0.001 compared with the GENIUS-CHD estimate. Similarly, no clear associations were identified for additional subsequent outcomes, including all-cause death, although we found a modest positive association between chromosome 9p21 and subsequent revascularization (odds ratio, 1.07; 95% CI, 1.04-1.09).

CONCLUSIONS:

In contrast to studies comparing individuals with CHD to disease-free controls, we found no clear association between genetic variation at chromosome 9p21 and risk of subsequent acute CHD events when all individuals had CHD at baseline. However, the association with subsequent revascularization may support the postulated mechanism of chromosome 9p21 for promoting atheroma development.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cromossomos Humanos Par 9 / Doença da Artéria Coronariana Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cromossomos Humanos Par 9 / Doença da Artéria Coronariana Idioma: En Ano de publicação: 2019 Tipo de documento: Article